Pfizer adds $600M to its venture group, with a special focus on the neurosciences field it just retreated from

Pfizer $PFE may have made an abrupt exit out of the neurosciences R&D arena, but it’s still interested in backing the biotechs willing to navigate the ultra-high risk field.